Skip to main content
NVDA+0.60%AAPL+0.36%GOOGL+0.93%MSFT+0.35%AMZN+0.31%TSM-0.16%SPCX+1.09%META+0.28%AVGO-1.10%TSLA+0.02%SKHY-1.36%MU+0.28%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.22%AUDUSD-1.08%GBPCHF+1.01%AUDJPY-0.98%USDCHF+0.86%GBPCAD+0.78%CHFJPY-0.70%EURGBP-0.68%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.56%EURAUD+0.56%EURUSD-0.54%USDTHB+0.54%NZDUSD-0.53%CADJPY-0.52%AUDCAD-0.46%EURJPY-0.43%GBPTRY+0.41%NZDJPY-0.39%NZDCHF+0.34%GBPHKD+0.32%EURCHF+0.31%USDTRY+0.29%GBPMXN-0.28%GBPJPY+0.26%AUDCHF-0.25%CADCHF+0.22%USDCNH-0.21%USDILS+0.16%GBPUSD+0.14%NZDCAD+0.12%USDJPY+0.11%EURCAD+0.10%AUDNOK+0.07%SGDJPY+0.05%AUDDKK+0.05%USDMXN+0.04%USDCOP-0.04%NZDMXN+0.03%USDHKD+0.03%AUDSGD+0.03%EURSGD-0.02%EURHKD-0.02%USDSGD-0.02%EURCNH-0.02%GBPSGD-0.02%NZDSGD-0.01%USDZAR+0.01%EURNZD-0.01%EURDKK-0.01%USDDKK0.00%GBPZAR0.00%EURNOK0.00%EURCZK0.00%USDNOK0.00%NOKJPY0.00%CHFNOK0.00%USDPLN0.00%EURZAR0.00%CHFSGD0.00%CHFSEK0.00%EURPLN0.00%EURSEK0.00%USDSEK0.00%PLNJPY0.00%USOIL-0.55%XPTUSD-0.40%XNGUSD+0.30%HG1-0.14%GAUUSD-0.03%XAUUSD-0.03%GAGUSD-0.01%XAGUSD-0.01%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.14%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.89%ZECUSDT+1.41%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+2.15%BCHUSDT-0.51%UNIUSD+0.03%LTCUSD+0.07%HBARUSDT+2.61%SUIUSD+1.13%TONUSD+15.77%TAOUSDT+0.09%AAVEUSD-3.50%DOTUSDT+2.53%ICPUSDT-3.24%ONDOUSDT-0.32%WLDUSDT+9.48%ARBUSDT-0.26%JUPUSDT-0.20%ATOMUSDT+1.22%INJUSDT-2.53%STXUSDT+17.38%FETUSDT+2.44%SEIUSDT+0.33%PYTHUSDT-2.14%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT+0.11%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.26%POLUSDT-3.28%AXSUSDT+0.93%FARTCOINUSDT-0.29%EOSUSDT+4.34%DYDXUSDT+3.80%GALAUSDT+4.75%ORDIUSDT+1.01%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.60%AAPL+0.36%GOOGL+0.93%MSFT+0.35%AMZN+0.31%TSM-0.16%SPCX+1.09%META+0.28%AVGO-1.10%TSLA+0.02%SKHY-1.36%MU+0.28%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.22%AUDUSD-1.08%GBPCHF+1.01%AUDJPY-0.98%USDCHF+0.86%GBPCAD+0.78%CHFJPY-0.70%EURGBP-0.68%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.56%EURAUD+0.56%EURUSD-0.54%USDTHB+0.54%NZDUSD-0.53%CADJPY-0.52%AUDCAD-0.46%EURJPY-0.43%GBPTRY+0.41%NZDJPY-0.39%NZDCHF+0.34%GBPHKD+0.32%EURCHF+0.31%USDTRY+0.29%GBPMXN-0.28%GBPJPY+0.26%AUDCHF-0.25%CADCHF+0.22%USDCNH-0.21%USDILS+0.16%GBPUSD+0.14%NZDCAD+0.12%USDJPY+0.11%EURCAD+0.10%AUDNOK+0.07%SGDJPY+0.05%AUDDKK+0.05%USDMXN+0.04%USDCOP-0.04%NZDMXN+0.03%USDHKD+0.03%AUDSGD+0.03%EURSGD-0.02%EURHKD-0.02%USDSGD-0.02%EURCNH-0.02%GBPSGD-0.02%NZDSGD-0.01%USDZAR+0.01%EURNZD-0.01%EURDKK-0.01%USDDKK0.00%GBPZAR0.00%EURNOK0.00%EURCZK0.00%USDNOK0.00%NOKJPY0.00%CHFNOK0.00%USDPLN0.00%EURZAR0.00%CHFSGD0.00%CHFSEK0.00%EURPLN0.00%EURSEK0.00%USDSEK0.00%PLNJPY0.00%USOIL-0.55%XPTUSD-0.40%XNGUSD+0.30%HG1-0.14%GAUUSD-0.03%XAUUSD-0.03%GAGUSD-0.01%XAGUSD-0.01%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.14%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.89%ZECUSDT+1.41%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+2.15%BCHUSDT-0.51%UNIUSD+0.03%LTCUSD+0.07%HBARUSDT+2.61%SUIUSD+1.13%TONUSD+15.77%TAOUSDT+0.09%AAVEUSD-3.50%DOTUSDT+2.53%ICPUSDT-3.24%ONDOUSDT-0.32%WLDUSDT+9.48%ARBUSDT-0.26%JUPUSDT-0.20%ATOMUSDT+1.22%INJUSDT-2.53%STXUSDT+17.38%FETUSDT+2.44%SEIUSDT+0.33%PYTHUSDT-2.14%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT+0.11%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.26%POLUSDT-3.28%AXSUSDT+0.93%FARTCOINUSDT-0.29%EOSUSDT+4.34%DYDXUSDT+3.80%GALAUSDT+4.75%ORDIUSDT+1.01%NOTUSDT+1.55%RONINUSDT+0.06%
RS

Roivant Sciences Ltd. (ROIV)

NASDAQ • Healthcare

$36.57
+$0.07 (+0.2%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$36.77
Day Range$36.23 - $36.96
Avg. Volume (3M)8.9M
Market Cap$26.4B
52 Week Range
$15.11$42.5
Next EarningsIn 39 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1.4M100%
Gross Profitminus cost of goods$1.1M80%

Fundamentals & Financials

Revenue (TTM)
$7.5M
Net Income (TTM)
-$266.2M
EPS (TTM)
-$0.38
ROA (TTM)
-5.02%
Current Ratio
16.72
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+19.9%Q1 2026-$0.24
+3.5%Q2 2026-$0.28
-10.1%Q3 2026-$0.33
Next

Nov 9

in 39 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -10.1%

Roivant Sciences trailed consensus on both the top and bottom line in the first fiscal quarter of 2026, reported August 6, 2026, as revenue of $1.4 million trailed the $2.1 million estimate (-30%) and adjusted EPS of -$0.33 trailed the -$0.30 estimate (-10%). Revenue fell 34% year over year to about $1.4 million (down from roughly $2.2 million a year ago), while gross profit came in at around $1.2 million and gross margin was about 80%. Operating results remained deeply negative, with operating income of roughly -$366.0 million, and net income improved 15% year over year to about -$189.8 million (from roughly -$223.4 million a year ago). For the next period, consensus calls for EPS of USD -0.41 on revenue of USD 3.3 million.

View full earnings history

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a NASDAQ-listed biotechnology company in healthcare that develops and builds drug-focused businesses. Trading on NASDAQ as ROIV, it has been public since its 2020 IPO and operates through a model centered on creating and advancing therapeutic programs in biotechnology.

Name
Roivant Sciences Ltd.
CEO
Matthew Gline
Website
roivant.com
Industry
Healthcare
Year Founded
2014
Employees
721

Today's Snapshot

AI-generated

The day ended with ROIV slightly higher at 36.57, while its sector was weaker. Shares changed hands at about half of its usual level.

Trading Volume

Below 10d avg (9.2M)

5.2M

vs S&P 500 Today

Inline with Market

+0.00%

Updated: September 30, 2026 at 20:19 UTC

ROIV Headlines

Roivant sets date for PHocus Phase 2 reveal

September 6, 2026

3 min read
View All News

Technical Indicators

3 Buy2 Neutral3 Sell
ROIV exhibits a cautiously negative technical picture marked by soft trend strength and weakening momentum. ADX under 20 points to a lackluster trend, while MACD is slightly negative and momentum is declining, and the stock trades below its short- and medium-term averages, signaling near-term pressure despite longer-term averages remaining higher. On-balance volume is unfavorable, indicating distribution, and ATR shows moderate volatility. The price sits near the classic pivot, limiting immediate directional conviction. Technical takeaway: Sell — short-term momentum and volume patterns weigh on the stock amid a weak trend.
All signals
  • EMA (5 indicators)$30.03 - $37.53
    Buy
  • RSI (14)45.52
    Neutral
  • Stochastic %K (14, 3, 3)20.87
    Neutral
  • MACD Level (12, 26)-0.02
    Sell

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
RVMDRevolution Medicines, Inc.
$205.26+0.4%
RPRXRoyalty Pharma plc
$58.36+0.2%
JAZZJazz Pharmaceuticals plc
$231.52-0.4%
SMMTSummit Therapeutics Inc.
$16.91+3.2%
BBIOBridgeBio Pharma, Inc.
$65.8-0.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.